Keywords:
pitavastatin calcium, pitavastatin calcium’s R&D Progress, Mechanism of Action for pitavastatin calcium, drug target for pitavastatin calcium.
Description:
This article summarized the latest R&D progress of pitavastatin calcium, the Mechanism of Action for pitavastatin calcium, and the drug target R&D trends for pitavastatin calcium.
Text:
pitavastatin calcium‘s R&D Progress
Pitavastatin Calcium is a small molecule drug that belongs to the class of HMG-CoA reductase inhibitors. It is primarily used in the treatment of various conditions related to congenital disorders, endocrinology, and metabolic diseases. The drug has been approved for the treatment of heterozygous familial hypercholesterolemia, hyperlipidemia, familial combined, dyslipidemias, hyperlipidemias, hypercholesterolemia, and hyperlipoproteinemia Type II.
The originator organization of Pitavastatin Calcium is Kowa Co., Ltd., a pharmaceutical company based in Japan. The drug received its first approval in Japan in July 2003, making it available for use in the Japanese market. It has also obtained approvals in other countries, indicating its global reach.
Pitavastatin Calcium has completed phase III clinical trials and is now approved for global markets.This signifies that the drug has undergone rigorous testing and has demonstrated its safety and efficacy in treating the indicated conditions.
The regulatory status of Pitavastatin Calcium is classified as “Priority Review.” This designation suggests that the drug has been given priority by regulatory authorities due to its potential to address unmet medical needs or provide significant therapeutic benefits compared to existing treatments.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for pitavastatin calcium: HMG-CoA reductase inhibitors
HMG-CoA reductase inhibitors, also known as statins, are a class of drugs used to lower cholesterol levels in the body. From a biomedical perspective, these medications work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the production of cholesterol in the liver. By blocking this enzyme, statins reduce the amount of cholesterol synthesized by the liver, leading to a decrease in total cholesterol and low-density lipoprotein (LDL) cholesterol levels.
Lowering LDL cholesterol is important because it is often referred to as “bad” cholesterol, as high levels of LDL can contribute to the development of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. By reducing LDL cholesterol levels, HMG-CoA reductase inhibitors help to prevent the formation of plaque and reduce the risk of cardiovascular diseases such as heart attacks and strokes.
It’s worth noting that statins not only lower LDL cholesterol but also have other beneficial effects. They can modestly increase high-density lipoprotein (HDL) cholesterol, often referred to as “good” cholesterol, which helps remove LDL cholesterol from the bloodstream. Additionally, statins have anti-inflammatory properties that may further contribute to their cardiovascular benefits.
Overall, HMG-CoA reductase inhibitors are widely prescribed medications for managing high cholesterol levels and reducing the risk of cardiovascular events. They are an important component of the treatment plan for individuals with hypercholesterolemia or those at high risk of developing cardiovascular diseases.
Drug Target R&D Trends for pitavastatin calcium
HMG-CoA reductase is an enzyme that plays a crucial role in the human body’s cholesterol synthesis pathway. It is responsible for catalyzing the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate, a key precursor in the production of cholesterol. By regulating the activity of HMG-CoA reductase, the body can control the amount of cholesterol synthesized. This enzyme is the target of statin drugs, which inhibit its activity, leading to a reduction in cholesterol levels. Maintaining proper HMG-CoA reductase function is essential for maintaining cholesterol homeostasis and preventing the development of cardiovascular diseases.
According to Patsnap Synapse, as of 7 Sep 2023, there are a total of 138 HMG-CoA reductase drugs worldwide, from 171 organizations, covering 56 indications, and conducting 3227 clinical trials.
The analysis of the target HMG-CoA reductase reveals a competitive landscape with several companies making significant progress in the development of drugs. Merck & Co., Inc., Hanmi Pharmaceutical Co., Ltd., and Organon & Co. are the leading companies with the highest number of approved drugs. The indications primarily focus on hyperlipidemias, dyslipidemias, hypertension, and hypercholesterolemia, indicating the potential of HMG-CoA reductase as a therapeutic target for cardiovascular and metabolic disorders. Small molecule drugs are progressing most rapidly, but there is also a presence of biosimilars such as herbal medicine. South Korea, the United States, and China are the countries developing fastest under this target, with China showing notable progress. Overall, the target HMG-CoA reductase presents a competitive landscape with opportunities for further development and innovation in the pharmaceutical industry.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In summary, Pitavastatin Calcium is a small molecule drug developed by Kowa Co., Ltd. It targets HMG-CoA reductase and is used in the treatment of various congenital disorders, endocrinology, and metabolic diseases. This drug has been approved for use in multiple countries, receiving its first approval in Japan back in 2003. The highest phase of clinical trials has been completed, and it has received priority review status, suggesting it may have significant therapeutic advantages.
